Tarsus Pharmaceuticals, Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.21 | $-0.43 | -104.8% | Miss |
| Q12026 FY2026 | $-0.46 | $-0.16 | +65.2% | Beat |
| Q42025 FY2025 | $-0.19 | $-0.20 | -5.3% | Miss |
Back to TARS overview · TARS holders · TARS KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.